Example 8 – Case Study – Shoulder Tendon HGH Frag


Example 8 – Case Study – Shoulder Tendon

The subject was a 23-year-old male professional footballer. The athlete incurred some fibre disruption at the junction of supraspinatus tendon insertion. The MRI indicated an area of 1.0 cm within the disruptive pathology. The MRI indicated that the disruption approached most superior facet of the greater tubercle of the humerus. Most of the affected area was the muscular portion of the junction. The MRI indicated an area of 1.0 cm within the disruptive pathology. The athlete indicated that the pain associated with the area was noticeable for around 5 weeks indicating some chronicity to the injury. The athlete had been restricted in both the range of motion he could employ for the injured site as well as the amount of weight bearing activity he could engage for the area. He had been finding it difficult to abduct the arm at the shoulder joint. He found difficulty in resisting inferior gravitational forces placed across the shoulder joint and found aggravation with any downward pull with the weight of the upper limb.

The subject undertook an intervention of AOD9604 (SEQ ID NO: 1 ) at 600 mg per dose. He applied one ml twice daily. The transdermal application was at 600 mg per ml. The total application was 30 ml.

Main Observations:
The athlete’s injury was resolved in three weeks. Subsequent MRI confirmed that that full integrity had returned to the functional area. The athlete also had returned to full weight bearing activities and rotation activity with the area. The athlete felt that there was no residual pain or discomfort associated with either movement or resistant work with the region. There was no awareness of the area with the return to exercise in either the rotation or weight bearing components. The athlete confirmed that there was no immediate pain or discomfort once the weight bearing capacity was fully resumed and no pain, inflammation or awareness of the injury could be identified post training. There was a re-aggravation of the injury at any stage. The athlete also noted that the pain associated with the injury had started to diminish by the end of the first week of the application of the transdermal.

Leave a Reply